Table 1.
Baseline characteristics of participants in this study.
| Characteristics | RA patients | Healthy controls |
|---|---|---|
| Total (female/male) | 41 (36/5) | 45 (37/8) |
| Age, mean (SD) (year) | 51.7 (16.3) | 49.6 (12.1) |
| Duration of disease, mean (SD) (year) | 6.2 (5.6) | — |
| DAS28 (CRP), mean (SD) | 4.4 (1.6) | — |
| DAS28 (ESR), mean (SD) | 4.7 (1.7) | — |
| CRP (mg/l), mean (SD) | 57.5 (61.2)∗∗∗ | 4.9 (3.8) |
| ESR (mm/h), mean (SD) | 49.9 (31.0)∗∗∗ | 11.3 (9.6) |
| RF (IU/ml), mean (SD) | 580.2 (950.2)∗∗∗ | 16.2 (10.9) |
| Anti-CCP (RU/ml), mean (SD) | 66.9 (63.8)∗∗∗ | 12.4 (8.1) |
| IgG (g/l), mean (SD) | 14.5 (3.4) | 13.8 (6.4) |
| IgA (g/l), mean (SD) | 3.3 (1.3) | 3.0 (1.7) |
| IgM (g/l), mean (SD) | 1.5 (0.7) | 1.1 (2.0) |
| WBC (109/l), mean (SD) | 7.8 (2.4) | 6.9 (4.2) |
| Lym (109/l), mean (SD) | 1.8 (0.6) | 1.9 (1.1) |
| PLT (109/l), mean (SD) | 347.9 (102.3)∗∗ | 196.3 (85.3) |
| Hb (g/l), mean (SD) | 111.2 (14.6)∗ | 145.5 (21.8) |
CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; RF: rheumatoid factor; anti-CCP: anti-cyclic citrullinated peptide; Ig: immunoglobulin; WBC: white blood cell; Lym: lymphocytes; PLT: platelet; Hb: hemoglobin. ∗ indicates RA vs. healthy controls (HC), p < 0.05. ∗∗ indicates RA vs. HC, p < 0.01. ∗∗∗ indicates RA vs. HC, p < 0.001.